Optimism grew this weekend that more good news is on the way from the clinical trials of the highly publicized obesity drug Acomplia (rimonabant).
While researchers are not scheduled to present new data from the RIO--Europe clinical trial at the American College of Cardiology scientific meeting in Orlando until Tuesday, March 8th, Sanofi Aventis has scheduled a “Medical Education Seminar” for Monday evening March 7th that seems to herald more encouraging results.
The Monday evening session is titled “Intra-Abdominal Adiposity and Cardiovascular Disease: A Novel Approach to Managing Multiple CV Risk Factors” and it will be chaired by Dr. Louis Aronne, president of the North American Association for the Study of Obesity.
Aronne, a professor at Weill Cornell Medical College in New York, previously has expressed the belief that Acomplia “could be a paradigm-shifting drug.”
The session Monday night is expected to focus on the role of Acomplia in reducing the abdominal fat that accumulates around the waist, which is widely viewed as a key indicator of cardiovascular risk.
Two-year results from the RIO-North America trial last November showed that waist circumference of trial participants was reduced by 3.1 inches for patients taking a daily 20 mg dose of rimonabant compared to 1.5 inches for trial participants taking a placebo.
Other researchers taking place in Monday night’s news conference include Dr. Luc Van Gaal, professor of Diabetology, Metabolism and Clinical Nutrition at Belgium’s University Hospital Antwerp, who has been the principal researcher on the RIO--Europe clinical trial.
He will be joined by Dr. Arya M Sharma, professor at the Michael DeGroote School of Medicine in Ontario; Dr. Valentin Fuster, Director of the Wiener Cardiovascular Institute and Kravis Center for Cardiovascular Disease; and Dr. Richard Gorlin, Professor of Cardiology at Mount Sinai Medical Center in New York.
Метки:
20 mg,
clinical,
drug,
Europe,
fat,
medicine,
obesity,
obesity drug,
results,
study,
Zimulti,
Новости
Посмотрите также
- New Acomplia Study Has More Good News for Obese Diabetics
The latest results of the last of four major Acomplia (rimonabant) studies added more good news to the mounting excitement about this breakthrough obesity drug.
Not only does Acomplia help obese people Acomplia (rimonabant) lose weight, raise their good cholesterol, lower their triglicerides, and reduce other cardiac risk [...]
- Zimulti Acomplia News — Oct. 2007 — News About Rimonabant
Diet Drug Taranabant Yields Encouraging Results With ‘Generally Mild’ Side-Effects Taranabant, which a year from now may have surged past (Acomplia) rimonabant as the world’s most eagerly awaited diet drug, made a low-key debut Oct. 24th when researchers reported that participants in a clinical trial achieved encouraging weight loss with [...]
- Study: Acomplia Produces Weight Loss and Metabolic Improvement
Quebec City, Canada, March 9, 2004 - Results of a Phase III clinical trial (RIO-Lipids or Rimonabant In Obesity) comparing rimonabant, the first drug in a new Acomplia (rimonabant) class called Selective CB1 Blockers (or SCB1Bs), to placebo found that overweight or obese patients with untreated dyslipidemia (high triglycerides, low HDL-cholesterol) lost [...]
- Report: Many Seek Accomplia, But the Hype Exceeds What Is Known So Far
At obesity treatment centers, nearly every Acomplia (rimonabant) patient now asks for Acomplia (rimonabant), the New York Times reports. But many medical researchers, the newspaper found, say that while rimonabant may be intriguing, “the mythology in the making is hardly justified by what is known so far.
[...]
- New Acomplia News Will Be Presented on March 8th
After a four-month dry spell during which there has been little news about development of the highly publicized obesity drug Acomplia (rimonabant) , researchers are scheduled to present new data from the RIO-Europe clinical trial at a scientific meeting in Orlando on Tuesday, March 8th.
The presentation of the first [...]
- New “News” — Well, Not Exactly — About Benefits of Acomplia
A new report in the prestigious New Acomplia (rimonabant) England Journal of Medicine has focused renewed attention on one of the earlier studies of Acomplia (rimonabant) — originally reported on in March 2004 — which found that overweight or obese patients with untreated dyslipidemia (high triglycerides, low HDL-cholesterol) lost almost 20 lbs [...]
If you enjoyed this post, please consider to leave a comment or subscribe to the feed and get future articles delivered to your feed reader.
Comments
Еще нет комментариев.
Извините, комментирование на данный момент закрыто.